Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

First European named patient sales of Voraxaze

Jan. 29, 2004

ARC-111, a novel topoisomerase I antitumor candidate

Jan. 29, 2004

Atiprimod granted orphan drug status for multiple myeloma

Jan. 28, 2004

Zentaris and Solvay to advance LHRH antagonists through collaboration

Jan. 28, 2004

German approval for three-month Eligard

Jan. 28, 2004

Epigallocatechin-3 gallate inhibits VEGF-induced angiogenesis in vitro

Jan. 28, 2004

Inex and Enzon partner to develop Onco TCS

Jan. 27, 2004

Velcade recommended for approval in Europe

Jan. 27, 2004

EntreMed identifies peptide fragment of tissue factor pathway inhibitor

Jan. 27, 2004

European approval recommended for Lysodren

Jan. 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.